Abstract. Long non-coding RNA (lncRNA)-NEF is a newly discovered lncRNA, which exhibits an inhibitory function on the metastasis of hepatocellular carcinoma, while its involvement in other types of malignancy are unknown. In the present study, tumor and adjacent healthy tissues were obtained from patients with non-small-cell lung cancer (NSCLC), and blood was obtained from patients with NSCLC and healthy individuals. Expression levels of lncRNA-NEF in tumor tissue samples, healthy tissue samples and serum were detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Receiver operating characteristic curve analysis and survival curve analysis were performed to evaluate the diagnostic and prognostic value of serum lncRNA-NEF for NSCLC. The effects of lncRNA-NEF overexpression in NSCLC cell lines on tumor cell proliferation, glucose uptake, glucose transporter 1 (GLUT1) protein expression and mRNA expression were investigated by Cell Counting kit-8 assay, glucose uptake assay, western blot analysis and RT-qPCR, respectively. It was identified that lncRNA-NEF was downregulated in NSCLC tissues, compared with healthy controls, and the serum level of lncRNA-NEF was negatively associated with primary tumor stage. Therefore, serum lncRNA-NEF may be a sensitive diagnostic and prognostic marker for NSCLC. Overexpression of lncRNA-NEF inhibited NSCLC cell proliferation and glucose uptake, and downregulated GLUT1 expression. Therefore, it can be concluded that lncRNA-NEF can target glucose transportation to inhibit the proliferation of NSCLC cells.
Introduction
Lung cancer is one of the most common types of human malignancy and is also one of the leading causes of cancer-associated mortality (1) . In developing countries, including China, environmental pollution has resulted in increased incidence and mortality rates of lung cancer in the past 10 years (2). Additionally, the incidence rate of lung cancer is predicted to increase in the future (2) . Non-small-cell lung cancer (NSCLC) is a major type of lung cancer and accounts for ~85% of all cases worldwide (3) . Despite efforts to develop treatment strategies, surgical resection remains the only radical treatment for NSCLC (4) . However, due to a lack of typical symptoms at the early stage of NSCLC, the majority of patients with NSCLC are diagnosed at an advanced stage, when surgical resection is inappropriate (5) . Therefore, early diagnosis and treatment for patients with NSCLC is critical to improve the survival rate.
The human genome not only transcribes mRNAs, which encode protein products, but also transcribes a large set of non-coding RNAs (ncRNAs), which serve key roles in almost all critical physiological and pathological processes (6) . Long ncRNAs (lncRNAs) are a subgroup of ncRNAs that are composed of >200 nucleotides (7) . It has been demonstrated that various lncRNAs, such as lncRNA PVT1 and lncRNA MEG, serve a number of roles in the onset, development and progression of NSCLC (8, 9) . lncRNA-NEF is a novel lncRNA, which exhibits a critical function in hepatocellular carcinoma (10) . Cancer development is characterized by the accelerated glucose metabolism, which provided energy for cancer development and progression (11) . Glucose transporter 1 (GLUT1) is as a key player in glucose uptake also participates in cancer biology (12) . The present study investigated the role of lncRNA-NEF in NSCLC and revealed that lncRNA-NEF can target glucose transportation, more specifically GLUT1, to inhibit the proliferation of NSCLC cells. The observation of the present study provides novel insights into the diagnosis and treatment strategies of NSCLC.
Patients and methods
Patients. The present study included 86 patients with NSCLC. All patients were pathologically diagnosed with NSCLC and treated at the First Hospital of Jilin University (Jilin, China) from July 2010 to January 2012. The total 86 patients included 52 males and 34 females, with an age range of 20- 5 cells. Lipofectamine 2000 and the DNA was mixed and kept at room temperature for 20 min to allow the formation of reagent-DNA complexes. The complexes were then incubated with the cells at 37˚C for 5-6 h to achieve transfection. Subsequently, the transfection mixture was immediately replaced with RPMI-1640 medium (37˚C) to avoid toxic effects.
Cell proliferation assay.
Transfected cells of all cell lines were collected during the logarithmic growth phase and a suspension with a cell density of 4x10 4 cells/ml was generated using RPMI-1640 medium. Subsequently, 100 µl cell suspension was added to each well of a 96-well plate. Cell Counting kit-8 (CCK-8, Sigma-Aldrich, Merck KGaA) solution (10 µl) was added to each well 24, 48, 72 and 96 h later. Following incubation at 37˚C for a further 4 h, the optical density value of each well at 450 nm was measured using a Fisherbrand accuSkan GO UV/Vis Microplate Spectrophotometer (Thermo Fisher Scientific, Inc.). OD values of control group at 9 h were set to 100, and other groups or other time points were normalized to the control group at 96 h.
Glucose uptake assay.
Transfected cells of all cell lines were collected during the logarithmic growth phase and a cell suspension with a cell density of 4x10 4 cells/ml was generated. Subsequently, 10 ml cell suspension (4x10 5 cells) was prepared using RPMI-1640 medium was added into each well of a 6-well plate. Following incubation for 24 h at 37˚C, the cells were washed with PBS once and incubated with 2 ml Krebs-Ringer-HEPES (KRH) buffer (120 mM NaCl, 25 mM Hepes, pH 7. Reverse transcription-quantitative PCR. Tumor and adjacent healthy tissue samples were ground in liquid nitrogen, followed by addition of TRIzol ® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) to extract total RNA. TRIzol ® reagent was also directly mixed with serum and in vitro cultivated cells to extract total RNA. RNA quality was assessed using a NanoDrop™ 2000 Spectrophotometer (Invitrogen; Thermo Fisher Scientific). RNA samples with an A260/A280 ratio between 1.8-2.0 were used to synthesize cDNA by reverse transcription using a SuperScript III Reverse Transcriptase kit (Thermo Fisher Scientific, Inc.). Reaction conditions were as follows: 25˚C for 5 min, 50˚C for 30 min and 85˚C for 15 min. A PCR reaction system was prepared using SYBR ® -Green Real-Time PCR Master mix (Thermo Fisher Scientific, Inc.) and the following primers were used: lncRNA-NEF forward, 5'-CTG CCG TCT TAA ACC AAC CC-3' and reverse, 5'-GCC CAA ACA GCT CCT CAA TT-3'; GLUT1 forward, 5'-AGG TGA TCG AGG AGT TCT AC-3' and reverse, 5'-TCA AAG GAC TTG CCC AGT TT-3'; and human β-actin forward, 5'-GAC CTC TAT GCC AAC ACA GT-3' and reverse, 5'-AGT ACT TGC GCT CAG GAG GA-3'. PCR reaction conditions were as follows: 95˚C for 45 sec, followed by 40 cycles of 10 sec at 95˚C and 40 sec at 60˚C. All data were quantified using the 2 -∆∆Cq method (13) . The relative expression level of lncRNA-NEF was normalized to the expression level of β-actin.
Western blot analysis. Total protein extraction from all in vitro cultured NSCLC cell lines was performed using radioimmunoprecipitation assay solution (Thermo Fisher Scientific, Inc.) and bicinchoninic acid assay was used for protein quantification. Subsequently, 10% SDS-PAGE gel electrophoresis was performed with 30 µg protein per lane, followed by transfer to polyvinylidene difluoride membranes. Membranes were blocked with 5% skimmed milk for 2 h at room temperature, followed by washing twice with TBS with 0.3% Tween (TBST) for 15 min each time. The membranes were then incubated with rabbit anti-GLUT1 primary (1:2,000; cat. no. ab15309; Abcam, Cambridge, UK) and rabbit anti-GAPDH primary antibodies (1:1,000; cat. no. ab8245; Abcam) overnight at 4˚C. Subsequently, the membranes were washed twice with TBST for 15 min each time and further incubated with anti-rabbit IgG-horseradish peroxidase-labeled secondary antibody (1:1,000; cat. no. MBS435036; MyBioSource, Inc., San Diego, CA, USA) at room temperature for 1 h. Following washing twice with TBST for 15 min each time, enhanced chemiluminescent (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) was added to develop a signal. Signals were detected using a MYECL™ Imager (Thermo Fisher Scientific, Inc.) and relative expression level of GLUT1 was normalized to endogenous control GAPDH using ImageJ v1.48 software (National Institutes of Health, Bethesda, MD, USA).
Statistical analysis. SPSS 19.0 (IBM Corp., Armonk, NY, USA) was used to perform all statistical analysis. All data are expressed as mean ± standard deviation. Comparisons between two groups and among multiple groups were performed by paired Student's t-test and one-way analysis of variance followed by Tukey post-hoc test, respectively. The Kaplan-Meier method was used to plot survival curves and survival curves were compared using a log rank t-test. P<0.05 was considered to indicate a statistically significant difference.
Results

Expression of lncRNA-NEF is downregulated in tumor tissues, compared with adjacent healthy tissues in patients with NSCLC.
The expression level of lncRNA-NEF in tumor tissues and adjacent healthy tissues obtained from 33 patients with NSCLC was detected by RT-qPCR. A significantly increased expression level of lncRNA-NEF was observed in adjacent tissues, compared with tumor tissues, for 30/33 patients with NSCLC (P<0.01; Fig. 1 ). By contrast, a significantly increased expression level of lncRNA-NEF was identified in tumor tissues, compared with adjacent tissues, for 1 patient with NSCLC (P<0.01; Fig. 1 ). No significant differences were revealed in the expression level of lncRNA-NEF in tumor tissues, compared with adjacent tissues, for 2 patients. These data demonstrate that downregulation of lncRNA-NEF is associated with the pathogenesis of NSCLC.
Levels of circulating lncRNA-NEF in serum are associated with the primary tumor stage. Levels of circulating lncRNA-NEF in the serum of patients with NSCLC and healthy controls were measured by RT-qPCR. Levels of serum lncRNA-NEF were significantly increased in healthy controls, compared with patients with all stages of NSCLC (P<0.05; Fig. 2) . Additionally, levels of serum lncRNA-NEF were significantly negatively associated with an increase in primary tumor stage (Fig. 2) . These data indicate that lncRNA-NEF is associated with the progression of NSCLC.
Diagnostic and prognostic value of circulating serum lncRNA-NEF for NSCLC.
Receiver operating characteristic curve analysis was performed to evaluate the diagnostic value of serum lncRNA-NEF for NSCLC. The area under the curve was 0.9421 with a 95% confidence interval of 0.9073-0.9769 (P<0.0001; Fig. 3A ). Patients were divided into high expression and low expression groups according to the median level of serum lncRNA-NEF. Follow-up was completed for 5 years for all patients to record the survival rates. The Kaplan-Meier method was used to plot survival curves for both expression groups and survival curves were compared using a log rank t-test. As depicted in Fig. 3B , the overall survival rate of patients with a high level of serum lncRNA-NEF was significantly increased, compared with the survival rate of patients lncRNA-NEF overexpression inhibits glucose uptake by NSCLC cells. Glucose uptake and metabolism provides energy for growth of healthy cells and cancer cells. Therefore, the effects of lncRNA-NEF overexpression on glucose uptake in NSCLC cells were investigated. As demonstrated in Fig. 5A , the glucose uptake level was significantly upregulated in the four transfected cell lines, compared with control cells (P<0.05). GLUT1 serves a key role in glucose uptake and metabolism. As depicted in Fig. 5B and C, lncRNA-NEF overexpression significantly increased the GLUT1 protein and mRNA expression levels in all four transfected cell lines, compared with control cells (P<0.05). These data indicate that lncRNA-NEF may inhibit glucose uptake in NSCLC cells by downregulating the expression of GLUT1, which could inhibit the growth of NSCLC.
Discussion
The present study investigated the role of lncRNA-NEF in NSCLC, a major type of lung cancer. It has previously been reported that that the development of numerous human malignancies is associated with altered expression patterns of certain lncRNAs, such as lncRNA PVT1 and lncRNA MEG (7) . In a previous study, 47 lncRNAs were revealed to be differentially-expressed in normal lung and NSCLC tumor tissues, compared with healthy tissues (14) . lncRNA-NEF is a novel lncRNA, which is downregulated in hepatocellular carcinoma (10) . In the present study, lncRNA-NEF was identified to be significantly downregulated in NSCLC tumor tissues, compared with adjacent healthy lung tissues, in the majority of patients with NSCLC. Additionally, serum levels of lncRNA-NEF were significantly negatively associated with an increase in primary tumor stage, which indicates a possible involvement of lncRNA-NEF in tumor growth. Notably, it has previously been demonstrated that lncRNA-NEF exhibits no significant effect on hepatocellular carcinoma growth (10), indicating differences in the pathogenesis of NSCLC and hepatocellular carcinoma.
It is understood that early diagnosis and treatment is critical for the survival of patients with the majority of cancer types, including NSCLC. Development of human disease is typically accompanied with changing levels of certain substances in the blood, and detecting these changes may provide biomarkers for the diagnosis and treatment of certain diseases (15) . The present study demonstrated that the level of serum lncRNA-NEF could be used to effectively distinguish patients with NSCLC from healthy controls. Additionally, a high level of serum lncRNA-NEF was associated with poor survival of patients. Therefore, lncRNA-NEF may serve as a diagnostic and prognostic biomarker of NSCLC, as well as a treatment target. lncRNA-NEF is a novel lncRNA with, to the best of our knowledge, an unknown expression pattern in other human diseases, except hepatocellular carcinoma (10) . Therefore, multiple biomarkers may be combined to improve the accuracy of diagnosis and prognosis.
The present study revealed that lncRNA-NEF overexpression significantly promoted the proliferation of NSCLC cells. Glucose uptake and metabolism provide energy for the proliferation of both normal cells and cancer cells (16) , and abnormally accelerated energy metabolism is considered a unique feature of cancer cells, compared with normal healthy cells (17) . Therefore, energy metabolism can be regarded as a target for the treatment of different types of malignancy (18) . As a major component of glucose uptake and metabolism, GLUT1 typically demonstrates upregulated expression during the development of numerous tumor types (19, 20) , including NSCLC. Upregulated expression of GLUT1 promotes tumor cell proliferation (21) and inhibits tumor cell death (22) . In the present study, lncRNA-NEF overexpression significantly inhibited glucose uptake in four NSCLC cell lines and downregulated the expression of GLUT1 in these cells. These data indicate that lncRNA-NEF overexpression may inhibit glucose uptake and metabolism of NSCLC cells by downregulating the expression of GLUT1, which may exert an inhibitory effect on the tumorigenesis of NSCLC. In conclusion, lncRNA-NEF was downregulated in NSCLC and a decrease in serum level of lncRNA-NEF was associated with an increasing size of primary tumor. Serum lncRNA-NEF is a sensitive diagnostic and prognostic marker for NSCLC. lncRNA-NEF overexpression inhibited NSCLC cell proliferation and glucose uptake, and downregulated GLUT1 expression. Therefore, it can be concluded that lncRNA-NEF targets glucose transportation to inhibit the proliferation of NSCLC cells. However, the present study is limited by the small sample size, and future studies with larger sample sizes are required to further confirm our conclusions.
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